Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary
Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte common stock, equal to 6.8% of the outstanding voting shares. All 18,312,735 shares are issued, outstanding, and directly owned by Fresenius Medical Care Holdings, Inc., with Fresenius Medical Care AG as indirect sole shareholder and deemed beneficial owner.
The stake percentage decreased from 8.4% to 6.8% solely because Humacyte’s total outstanding common shares increased to 269,638,156 as of June 12, 2026; Fresenius has neither acquired nor disposed of Humacyte shares since its initial 2021 filing. The amendment also notes that Mollie Miller became a Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. effective May 1, 2026.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 18,312,735 shares
Percent of class: 6.8%
Total shares outstanding: 269,638,156 shares
+3 more
6 metrics
Beneficial ownership
18,312,735 shares
Humacyte common stock reported by Fresenius Medical Care Holdings, Inc.
Percent of class
6.8%
Portion of Humacyte outstanding voting shares held by Fresenius entities
Total shares outstanding
269,638,156 shares
Humacyte common shares outstanding as of June 12, 2026
Shares outstanding baseline
222,019,108 shares
Humacyte shares outstanding on May 11, 2026 from Form 10-Q cover page
Additional shares issued
47,619,048 shares
Humacyte shares issued on June 12, 2025 per Prospectus Supplement
Prior reported ownership
8.4%
Fresenius percentage of Humacyte reported in Amendments Nos. 7 and 8
Key Terms
beneficial owner, shared voting power, shared dispositive power, percent of class, +2 more
6 terms
beneficial owner financial
"FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
percent of class financial
"Percent of class represented by amount in Row (11) 6.8 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Business Combination Agreement financial
"exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement"
A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.
Schedule 13D regulatory
"previously filed a statement on Schedule 13G to report the acquisition"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
FAQ
What percentage of Humacyte (HUMA) does Fresenius currently hold?
Fresenius reports beneficial ownership of approximately 6.8% of Humacyte’s outstanding voting common shares. This percentage is based on 269,638,156 Humacyte shares outstanding as of June 12, 2026, combining previously outstanding shares and additional shares issued by Humacyte.
Why did Fresenius’s ownership percentage in Humacyte (HUMA) fall from 8.4% to 6.8%?
The reported ownership percentage fell from 8.4% to 6.8% because Humacyte’s total outstanding common shares increased. Fresenius states it has not bought or sold Humacyte shares since its initial Schedule 13D, so the change reflects dilution from new shares issued by Humacyte.
What management change at Fresenius is mentioned in this Humacyte (HUMA) filing?
Effective May 1, 2026, Mollie Miller was appointed Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. She serves as Director of Taxes at the company and is a U.S. citizen, with her business address listed at the firm’s New York location.